- Science
- Strategy
- Speed
GI Innovation will lead the next innovative generation of drug development using the 3S strategy.
Experts in immunology, medical science, and others are developing an innovative drugs based
on scientific research and their technology platform.
01
SCROLL
TECHNOLOGY
SMART PLATFORM
GIINOVATION SMART™ PLATFORM TECHNOLOGY
-
- 01GI-SMART™
-
GI-SMART™ is a GI Innovation’s proprietary platform that enables
efficient discovery of lead product and development of cell-line
through high-throughput screening system.
-
- 02GI-SMARTab™
-
GI-SMARTab™ program is designed to create bispecific antibodies
with the optimal combination of therapeutic antibodies through
GI-SMART™ platform.
PROJECT
NEW DRUG DEVELOPMENT
New drug development in progress based on GI-SMART™ platform
pr room
press release
-
- GI Innovation and GI Biome Advance to the Semi-finals of the XPRIZE Healthspan with Anti-Aging Potential of GI-102 and GIB-7 Combination Therapy
- -GI Innovation and GI Biome have been selected as a Top 40 semi-finalist in the XPRIZE Healthspan competition among 600 registered teams from 58 countries-Selected as one of 8 teams to pitch at the XPRIZE Investor Summit in New York-The team is now competing for one of the largest prize pools in the history of XPRIZE XPRIZE Healthspan website GI Innovation, a South Korean biotech company, announced on May 13 that it has been selected as a semi-finalist in the XPRIZE Healthspan competition in collaboration with its sister company GI Biome. The XPRIZE Healthspan semi-finals ceremony is taking place in New York from May 12 to 14, inviting the top 40 semi-finalist teams out of more than 600 pre-registered team. The company has not only advanced to the semi-finals but has also been selected as one of the 8 teams among the 40 semi-finalists, earning an exclusive opportunity to present its vision and innovations to high-profile, large-scale global investors. XPRIZE, a U.S.-based nonprofit foundation, is the recognized global leader in designing and executing large-scale competitions to solve humanity's greatest challenges. For over 30 years, our unique model has democratized crowd-sourced innovation and scientifically scalable solutions that accelerate a more equitable and abundant future. Semi-finalists are selected by an expert committee using rigorous guidelines and advancement into this elite group is seen as recognition of exceptional scientific vision and execution.The XPRIZE Healthspan competition, in which the joint GI Innovation - GI Biome team is competing, aims to discover breakthrough treatments that can slow or prevent age-related degeneration. The competition offers a record-breaking total prize pool of approximately USD $101 million (KRW 140 billion). Through being selected as a semi-finalist team, GI Innovation will receive a prize of approximately USD $250,000 (approx. KRW 350 million) to support the next stage of clinical trial. Only the top 10 teams from the semi-final round will advance to the grand final.Milestone 1 Winners of the XPRIZE Healthspan at the Awards Ceremony (Source: GI Innovation)◆ ‘Anti-Aging’ Strategy with Immune Booster GI-102 and Microbiome-Based GIB-7 CombinationThe GI Innovation-GI Biome joint team proposed a combination therapy consisting of GI-102, an immune-boosting drug, and GIB-7, a microbiome-based synbiotic, as a novel anti-aging approach.Clinical studies have shown that GI-102 potently activates CD8+ T cells and NK cells at high doses, allowing those immune cells to safely attack a range of tumor types including melanoma, kidney, lung and bladder cancers. However, at low-doses, it selectively expands and activates NK cells, which are critical for clearing senescent cells and cellular debris, playing a vital role in delaying aging and maintaining physiological functions. Based on this mechanism, GI Innovation is pursuing the use of low-dose GI-102 as an NK cell enhancer.GIB-7 is a premium synbiotic developed using GI Biome’s proprietary Microbiome+ Herbal Therapy platform. It combines three patented probiotic strains with herbal ingredients. Clinical trials in elderly volunteers at Seoul National University Hospital have already completed. In aging mice model, GIB-7 demonstrated △ increased beneficial gut microbiota, △ regulation of circadian rhythm, and △ improved muscle strength.“We entered this competition with the goal of winning, and it is a great honor to have passed the first gateway, proving the scientific innovation of both GI Innovation and GI Biome,” said Dr. Myoung-Ho Jang, CEO of GI Innovation. “The upcoming clinical trial will be conducted in collaboration with Dr. Katherine Samaras, a key opinion leader on anti-aging research from the Garvan Institute of Medical Research in Australia. We are also in discussions to incorporate PG-102 (GLP-1/GLP-2 bispecific), developed by Progen, to enhance cognitive function. Through this competition, we will do our utmost to realize our global vision of expanding from treatment to prevention.”
2025-05-13 -
- GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy
- From the left, Rhee Byung-geon, Chairman and CEO of GI Innovation, Dr. Crystal Quin, CEO of LaNova Medicines, and Jang Myoung-ho, CSO of GI Innovation. (Source: GI Innovation)[Seoul, Jan 22, 2025] GI Innovation announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development of GI-102 and ADC pancreatic cancer combination therapy.This MOU was held on January 15th, local time, during JP Morgan Healthcare Conference (San Francisco, USA). The two companies have been conducting combination therapy study of the immuno-oncology drug GI-102 and ADC LM-302 targeting Claudin18.2 and recently observed excellent anticancer activity in a preclinical pancreatic cancer model.Both substances are in the clinical stage. GI-102 has completed phase 1 clinical trial in the US and Korea and can quickly enter phase 2. LM-302 is currently in phase 3 clinical trial for 3L and above gastric cancer in China. Pancreatic cancer has no approved immunotherapy, and the only approved treatment is a chemotherapy cocktail, but its treatment efficacy is low and its toxicity is high. Through this agreement, both companies will conduct clinical trial targeting patients with metastatic pancreatic cancer. Dr. Myoung Ho Jang, CSO said, “We are delighted to be conducting a combination study with LaNova, which is recognized by global pharma companies. LaNova’s ADC, which directly destroys tumor cells to increase the response rate, and GI-102, which can enhance immune memory to increase overall survival, are expected to be a combination therapy that can change the pancreatic cancer treatment paradigm.” “GI-102 exemplifies GI Innovation’s robust R&D capabilities in immunotherapy. We are excited to explore its combination with LaNova's Claudin18.2 ADC, LM-302, which holds the potential to provide a novel therapeutic option for pancreatic cancer patients” Dr. Crystal Qin, LaNova CEO emphasized.
2025-02-02
